HF 464: Relating to price transparency and cost-sharing for prescription drugs, and including applicability provisions

What it does

This bill relates to price transparency and cost-sharing for prescription drugs. The bill requires a manufacturer to file an annual report with the commissioner of insurance (commissioner) that discloses the wholesale acquisition cost for all prescription drugs manufactured by the manufacturer that were sold to a person in this state in the immediately preceding calendar year. The first report that is due covers all prescription drugs sold to a person in this state on or after January 1, 2021. “Wholesale acquisition cost” or “cost” is defined in the bill as the manufacturer’s list price for a prescription drug for wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates, or reductions in price, for the most recent month for which the information is available, as reported in wholesale price guides or other publications of drug or biological pricing data.

In plain words

1. February 10, 2021Filed in the House and sent to the Commerce committee